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CHAPTER 1 
INTRODUCTION 
1.1 Overview 
Deoxyribonucleic acid (DNA) is a mixed polymer of the four nucleotides adenine, 
guanine, cytosine and thymine linked by phophodiester bonds. The sequence of these 
letters determines the genetic makeup (genotype) of an organism. Any change of this 
sequence can lead to mutations which in turn can alter the observable traits of an 
organism known as phenotype. Surprisingly, not all phenotypic changes are due to 
changes in the genotype. Phenotypic changes occur without altering the primary 
sequence of DNA are epigenetic changes. In the conventional view, DNA is a stable 
molecule having following features to protect the integrity of the genetic information.  
DNA exists as a double stranded helix segregating the genetic information equally in 
the semi-conservative replication during cell divisions. The presence of 2´-H instead of 
2´-OH in pentose sugar makes DNA more inert compared to RNA and well suited to 
store the genetic information in organisms. The stacking of nitrogen bases inside the 
structure shields the bases from both endogenous and exogenous damaging agents. 
However, when DNA damage does occur, several DNA repair mechanisms (Base 
Excision Repair, Nucleotide Excision Repair, Mismatch Repair etc.,) have evolved to 
protect the damaged DNA bases or strands. The double stranded-ness plays a role in 
repair as well providing a template to find the missing information in the damaged DNA 
strand.  
In spite of all the above protective mechanisms, the cytosine in DNA undergoes a 
multitude of changes to add an extra layer of information to the primary sequence. This 
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versatility has been achieved through covalent modifications of the base using a set of 
enzymes. The mechanics and the significance of RNA cytosine modification have long 
been studied and continues to expand [1-2]. In contrast, modification of cytosine in DNA 
comes with rewards as well as risks. The targeted deamination of cytosines in the 
immunoglobulin genes generates diversity in antibodies while misregulation of the 
process leads to B-cell lymphomas [3]. The marking of cytosines with a methyl group 
distinguish self DNA from foreign in prokaryotes. DNA methylation in eukaryotes is 
essential for gene regulation and epigenetic modification although it comes with the price 
of frequent 5mC to T mutations [4]. The long-term goal of our lab is to study the 
prevention as well as promotion of mutations in life processes. My thesis work explores 
the importance as well as deleterious effects of cytosine deamination, cytosine 
methylation and recently discovered DNA demethylation to the living cells. 
1.2  Cytosine deamination and the APOBEC family of proteins 
The deamination of cytosine to uracil (Figure 1.1) is a spontaneous process 
(hydrolytic deamination) that occurs at a rate of 100-500/eukaryotic cell /day and the rate 
of deamination of single stranded DNA is 140 fold higher compared to the double 
stranded DNA deamination [5]. The APOBEC (Apolipoprotein B mRNA editing enzyme- 
catalytic polypeptide) family of proteins in higher vertebrates has evolved to catalyze the 
same reaction as single stranded specific DNA or RNA cytosine deaminases (Figure 
1.2).  APOBEC is the only family of enzymes known in biology that damages DNA or 
RNA to achieve its biological function such as antibody maturation [6] or retrovirus 
restriction [7].  
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Figure 1.1 Hydrolytic deamination of cytosine.  Cytosine deamination is initiated by the 
nucleophilic attack of a free water molecule at the C4 carbon of a cytosine (left) and 
leaving the amino group as ammonia resulting a uracil (right).  
 
 
 
4 
  
 
 
Figure 1.2 Members of the human APOBEC family. APOBEC1 is a single stranded RNA 
cytosine deaminase. The other members have either no activity on nucleic acids or are 
single stranded DNA cytosine deaminases. All enzymes of the family posses at least 
one cytosine deamination sequence motif as highlighted in the box. A modified figure 
from the reference [8].  
 
APOBEC1 was the first member to be discovered and has a role in lipid 
metabolism [9-10]. This is a single-stranded RNA cytosine deaminase although it can act 
on DNA as well [11]. The known proteins of the human APOBEC family with their 
properties are summarized below (Table 1.1).  
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Table 1.1 A summary of known members in human APOBEC family and their      
properties 
Name Tissue expression Enzyme activity Associated function 
Apobec1 GI track RNA/DNA 
deaminase 
ApoB mRNA editing 
Apobec2 Heart and skeletal muscle None unknown 
Apobec3A Primary monocytes, 
keratinocytes 
DNA deaminase Viral and  retrotransposon 
restriction 
Apobec3B T cells, PBMC DNA deaminase Viral and  retrotransposon 
restriction 
Apobec3C Many tissues and cancer 
cell lines 
DNA deaminase Viral and  retrotransposon 
restriction 
Apobec3DE Many tissues none Viral restriction 
Apobec3F Many tissues DNA deaminase Viral and  retrotransposon 
restriction 
Apobec3G Many tissues DNA deaminase Viral and  retrotransposon 
restriction 
Apobec3H Poorly expressed due to 
a premature stop codon  
Unknown Viral restriction once 
expression is optimized 
Apobec4 unknown none unknown 
AID Activated B-cells, 
primodial germ cells 
DNA deaminase Antibody maturation 
Adapted from the references [12-13] 
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In performing the cytosine deamination reaction on polynucleotide substrates, 
APOBECs show DNA/RNA sequence preferences (Table 1.2). Typically APOBECs have 
a strong preference for the base -1 from the target cytosine and a weaker preference for 
-2 base. In one study, 89% of all the mutations caused by activation induced deaminase 
(AID) occurred within WRC sequence context where W is A or T and R is purine [14]. In 
another study, 75% of mutations caused by APOBEC3G were in CCC sequence [15]. 
Other proteins in the family are less well studied but also have DNA sequence 
preferences (Table 1.2). However, these sequence determining amino acid residues of 
the proteins were not understood. In this study, putative DNA binding regions were 
swapped among the APOBECs and the role of those amino acid residues in sequence 
specificity determination was tested.  
Table 1.2 APOBEC enzymes with known substrate sequence preferences 
Enzyme DNA/RNA sequence preference References 
Apobec1 5´-TC /  C and 6666 ApoB mRNA [16] 
Apobec3A 5´-TC /5´-CC [17] 
Apobec3C 5´-TC > 5´-CC [18] 
Apobec3DE 5´-WC [19] 
Apobec3F 5´-TC [20] 
Apobec3G 5´-CCC [16],[15] 
AID 5´-WRC [14] 
Underlined C is the target of deamination. W is A or T and R is purine 
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1.2.1 Innate immunity and the APOBEC3 cluster 
The mammalian immune system carries out a myriad of protective mechanisms 
to keep pathogens in check. The immune reaction we make against the pathogen is 
known as the immune response and there are two types of responses named innate and 
adaptive. The innate immune response is readily available to combat an array of 
pathogens but does not lead to a lasting immunity or immunological memory. This  
response is not specific for a particular pathogen. Multiple defense mechanisms 
represent the eukaryotic innate immune system including phagocytic cells, antimicrobial 
peptides, signaling molecules like interferons etc., In contrast to innate immunity, 
adaptive immune response is specific for a pathogen and it develops as an adaptation to 
the particular pathogen or pathogen derived molecules (antigens). APOBECs play a 
central role in both of these arms, APOBEC3 cluster of proteins in innate immunity and 
AID in the adaptive immune response. 
APOBEC3 genes in humans form a sub-branch of the family (Figure 1.2) 
originated through tandem duplications of an ancestral APOBEC3 gene [21]. Six of the 
human APOBEC3 genes (APOBEC3A to APBEC3G) form a 130 kb cluster on 
chromosome 22 [22]. Although, the region containing the APOBEC3 cluster on human 
chromosome 22 is syntenic to a segment of murine chromosome 15, there is only one 
APOBEC3 gene in mice [23]. Complex rearrangements of the APOBEC3 locus due to 
retroviral activity may have contributed to the expansion of the multiple APOBEC3 
proteins in primates. In support of this hypothesis, ~ 19% of the human APOBEC3 locus 
comprises relics of mainly LTR type retroelement DNA [23].  The two APOBEC3 proteins 
I studied during my thesis work (APOBEC3A and APOBEC3G) are described below in 
detail. AID will be described in the context of adaptive immunity. 
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1.2.2 APOBEC3A (A3A) 
A3A is a single domain cytosine deaminase (Figure1.2) and can enter the 
nucleus [24]. A3A inhibits retrotransposition of LINE-1 elements [24] and adeno-
associated virus 2 (AAV2) [17]. Although a recent study showed that A3A is capable of 
restricting HIV-1 in human myeloid cells [25], it is in general inactive against HIV-1 in cell 
lines [26]. This inability of A3A to act on HIV-1 seems to be due to the improper targeting 
of the protein into the viral nucleoprotein complex. The forced incorporation of A3A as an 
A3G-A3A hybrid facilitated not only packaging the protein into HIV-1 but in inducing a 
high level of editing (cytosine deamination) and replication blockade [27]. Over 
expression of A3A leads to hyper-editing of papillomavirus genomes [28] and transfected 
plasmid DNA [29]. A recent study indicated the potential of A3A to activate the DNA 
damage response and cell cycle arrest when the protein is over expressed [30]. This 
ability seems to be unique to A3A as authors have compared A3B, A3C and A3G along 
with A3A in the study. Another recent study proposed a new role for A3A in DNA 
catabolism based on mitochondrial DNA editing by A3A [31]. The expression of human 
A3A is initiated from two different methionine codons (M1 and M13) resulting in two 
isoforms that are visible as a doublet on a western blot [32]. In this study, I examined the 
ability of A3A to deaminate cytosine and 5-methyl cytosine both in vivo and in vitro. 
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1.2.3 APOBEC3G (A3G) 
  Among APOBEC3s, A3G is the most intensively studied member. A3G inhibits 
the replication of HIV-1, if the virus is deficient for the viral infectivity factor (Vif) protein 
(Figure 1.3) [33].  Therefore, the function of HIV-1 Vif is to counteract A3G activity by 
targeting the protein for polyubiquitilation and proteasomal degradation [34-35]. In the 
absence of Vif, A3G restricts HIV-1 using at least two different mechanisms. The 
catalytically inactive CDA (Figure 1.2) domain is essential for binding viral RNA, 
interactions with HIV-1 Gag and incorporation into HIV-1 virions [36-38]. The catalytically 
active CDA is required to introduce C to T mutations in the reverse transcribing DNA 
copy of the viral genome (G to A mutations in viral RNA) as the other mechanism to 
impair the virus. Due to this hypermutation event, essential viral proteins may be 
inactivated or cellular repair enzymes may degrade the viral cDNA [39-41]. A clear 
understanding of the structure of the A3G protein and its interaction with nucleic acids is 
paramount to elucidate these unanswered questions. 
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Figure 1.3 Role of APOBEC3G and Vif in retroviral restriction and infection. APOBEC3G 
(maroon) and Virulence infectivity factor (VIf- pink circle) are key determinants of 
retroviral infectivity. In the absence of Vif, APOBEC3G is incorporated into HIV-1 virions 
along with the viral genomic RNA. HIV-1 Vif protein targets APOBEC3G protein for 
proteasomal degradation in the producer cells (cells that propagate viruses). On the 
contrary, if APOBEC3G escapes Vif, it can enter into the budding virions and later into 
the target cell which is free from viruses but get infected subsequently. The AOBEC3G 
in target cells can deaminate the newly synthesizing minus DNA strand of the virus. RT 
– Reverse transcriptase. Adapted from a figure in reference [7]. 
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1.2.4 Structure of APOBEC3G carboxy terminal domain (A3G-CTD)  
Recent solution structures of APOBEC3G carboxy terminal domain by NMR 
spectroscopy [42-43] and the crystal structure of the same domain by X-ray 
crystallography [44] shed light into the catalytic pocket of the enzyme (Figure 1.4) and 
the DNA binding regions (Figure 1.5). The catalytic pocket of the A3G-CTD contains a 
Zn2+ ion (red dot) coordinated by Cys 288, Cys291, His 257 and a water molecule 
(cyan). This structure provides the insight into how this class of enzymes interacts with 
DNA and performs catalysis. 
 
Figure 1.4 Catalytic pocket of A3G-CTD. The active site of A3G-CTD contains a Zn+2 ion 
(red) coordinated by C288, C291, H257 and a water molecule (cyan). E259 hydrogen 
bonds with a H2O molecule and presumably activates for an attack at C4 of target 
cytosine of single stranded DNA. PDB: 3E1U [44].  
Although both the NMR and crystal structures predicted the path of DNA binding 
to the protein (Figure 1.5) there are significant differences between the two structures.  
These structures were not solved bound with DNA, and the authors used different 
criteria to determine the putative DNA binding regions. The differences between the two 
 
12 
  
structures arise mainly due to the loops of the protein appear to acquire different three 
dimensional structures in solution (NMR) compared to crystalline form. The position of 
the “loop1” is substantially different in the two structures. To identify the DNA binding 
regions, the authors relied on two different criteria.  Chen et al [42] used NMR chemical 
shift perturbations in the presence of a 5´-CCT oligomer to identify the amino acids that 
may interact with DNA. In contrast, the study of Holden et al [44] was based on a deep 
groove present in the X-ray structure to determine the DNA binding residues.   
 
Figure 1.5 The structure of A3G-CTD determined by NMR (left-PDB: 2JYW) and X-ray 
crystal structure (right-PDB: 3E1U) are shown. The predicted path of DNA in each 
structure along with two amino acids has been shown to illustrate the difference between 
the two structures. Adapted from a figure in reference [45].  
Both groups performed site directed mutagenesis and deaminase assays to 
narrow the list of residues down to one (Region-2, X-ray structure) or two (Region-1 and 
Region-2, NMR structure) putative DNA binding regions (Figure 1.6). To obtain the NMR 
structure, Chen et al. used a more soluble variant of A3G-CTD with 5 mutations called 
2K3A and they are shown in Figure 1.6 aligning with AID amino acid sequence. L234K 
Predicted path of DNA
R215
R213 R215
R213
Zn2+
Zn2+
D316
R313
R313
D316
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and F310K mutations improved the solubility of the variant protein whereas C243A, 
C321A and C356A minimized the intermolecular disulfide bond formation [42]. The 
experiments in my thesis work were carried out using the A3G-CTD-2K3A variant.  
 
 
Figure 1.6 Sequence alignments of human AID and A3G-CTD. The amino acids shared 
by both the proteins are shown in blue. The residues changed to obtain 2K3A variant is 
indicated with arrows. The two putative DNA binding regions are underlined (DBD-1 and 
DBD-2). Two cysteines and the histidine that coordinate the Zn2+ in the catalytic pocket 
have been indicated with a box. Adapted from a figure in reference [45]. 
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1.2.5 Adaptive immunity and AID 
Adaptive immunity is also known as the humoral immunity as it is mediated by 
antibodies (Figure 1.7) produced by B-cells against the antigens. Two key features of 
humoral immunity are the immunological memory and the generation of antibody 
diversity. Antibody diversity is critical to the success of higher vertebrates to overcome a 
limitless number of antigens using a limited number of antibody genes. The origin of this 
diversity was an enigma for a long time. The early ideas of antibody gene diversification 
were developed on a theoretical basis due to the lack of sufficient experimental tools 
[46]. Although many theories were postulated to explain the mechanism of primary 
antibody diversity, recombinant DNA technology provided the direct evidence to 
characterize the mouse immunoglobulin gene loci.  Tonegawa et al. were the first to 
come up with the experimental data for the gene rearrangements of the antibody gene 
[47]. 
 
Figure 1.7   Schematic of the antibody molecule. A typical antibody molecule consists of 
two heavy chains (longer chains in the middle) and two light chains (shorter outside 
chains).  The N-terminus is specialized to bind to the antigen and it shows high amino 
acid variability. Relatively the C-terminus has a constant amino acid composition. The 
disulfide bonds between the chains are shown.  
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1.2.6 Generation of antibody diversity 
In humans and mice, antibodies gain diversity through three main processes 
called V(D)J recombination, somatic hypermutation (SHM), and class switch 
recombination (CSR) (Figure 1.8 ).  V(D)J recombination is a combinatorial process that 
combines three types of protein coding DNA units called variable(V), diversity (D), and  
junction (J) segments. The identification of RAG1 and RAG2 (recombination-activating 
genes) as the “V(D)J recombinase” by the Baltimore laboratory was a major contribution 
to delineate the underlying mechanism of this process [48-49]. There are scores of V, D 
(only in heavy chains) and J-segments in human immunoglobulin gene region. During 
early B-cell development, each cell creates a unique combination representing one 
region from each category [V (D) and J] to form the variable region. This happens prior 
to the exposure of B-cells to any antigen and is capable of producing millions of clones 
each capable of making a distinct antibody.   
However, the primary repertoire of antibodies generated through V(D)J 
rearrangement alone was not sufficient to provide high affinity antibodies ( Ka 10
9 M-1 ) in 
any organism [50]. There were speculations of mutational processes at the N-terminus 
of the antibody molecule to introduce the additional diversity and Lederberg was one of 
the pioneers to put forward this hypothesis [51]. Brenner and Milstein bolstered 
Lederberg’s 1959 proposal of the mutational process suggesting an antibody diversity 
might be achieved through a localized DNA synthesis driven by an error-prone repair of 
a lesion created by an unidentified DNA cleaving enzyme [52].  
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1.2.7 Discovery of AID 
After 30 years, Muramatsu et al discovered the APOBEC protein, named 
activation induced deaminase (AID) as the mutator enzyme [53].  The discovery of AID 
is one of the conceptual breakthroughs in understanding the genetics of antibody gene 
diversification. AID is expressed mainly but not exclusively in the germinal center B cells 
[53-54]. This is a single stranded DNA specific cytosine deaminase [55-56] and the 
conversion of cytosine to uracil by AID is required for both somatic hypermutation (SHM) 
and class switch recombination (CSR). Once AID deaminates cytosines in DNA into 
uracil, the downstream cellular pathways act differently in the two processes either to 
introduce point mutations in the case of SHM or region specific recombinations in CSR 
(Figure 1.8). Some animals like chickens and pigs can perform an additional AID-
dependent diversification of antibody genes called gene conversion [57] but it will not be 
discussed here.  
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Figure 1.8 Molecular mechanisms underlying antibody maturation. The human antibody 
gene loci contain scores of V (variable), D (diversity) and J (junction) sequences 
upstream to the constant gene segments. V(D)J recombination takes place in two 
steps.  A “D” segment recombines with a “J” segment followed by a “V” region combing 
with already rearranged “D-J” segment. The shuffling of gene segments will allow the 
primary antibody repertoire to reach millions of different combinations. During somatic 
hypermutation, AID introduces point mutations to the already rearranged V(D)J region 
that represents the variable region of the antibody molecule. Asterisks within the variable 
region depict the point mutations. Class switch recombination is a region specific 
recombinational process in which AID mediated point mutations lead to strand breaks in 
S (switch) regions of antibody genes. The downstream processes resolve those strand 
breaks while switching the antibody classes from IgM to a different isotype such as IgG 
rendering a different effector function to the antibody. During this process, the 
intervening DNA segment in two S-regions is eliminated as a circle.  
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1.2.8 Somatic hypermuatation (SHM) 
SHM is a process whereby the affinity of an antibody molecule is increased 
toward a particular antigen through the introduction of point mutations to the variable 
region of the antibody gene (Figure1.8). Some of these mutations are favorable to make 
a better fit with the antigen and are clonally selected to proliferate whereas the B-cells 
with deleterious mutations are discarded through apoptosis [46].  SHM results in a 
mutation rate in the immunoglobulin genes of about 1 mutation per 1000-10000 base 
pairs per cell division, a rate which is a million fold higher than the background mutation 
rate (Berek, 1998). One of the remarkable intrinsic features of SHM is that this 
mutational process directs only to  ~ 2 kb region of the antibody variable gene region 
[58] out of 3 billion base pair human genome.  
1.2.9 Class Switch Recombination (CSR) 
While SHM is a mutational process to increase the affinity of the variable regions 
of both light and heavy chains, CSR is a region specific recombinational process that 
occurs only in heavy chain genes of the antibody molecules (Figure 1.7). The first 
antibody isotype to produce prior to CSR is IgM with the constant gene µ. CSR 
exchanges the µ constant region with another (e.g. γ) to alter the effector function of the 
antibody. The different antibody isotypes with different effector functions will determine 
the half life of the antibody, tissue localization etc. Triggering the CSR machinery at S-
regions (Figure 1.8) is precisely regulated by the cytokines with induced S-transcripts at 
the 5´ repetitive S-regions [59]. For example, the stimulation of mouse B-lymphocytes 
with interleukin (IL) 4 induces CSR to IgG1 and IgE. AID initiates CSR by deaminating 
cytosines in single stranded S-regions creating a U●G mismatch [60]. The U●G 
mismatches introduced by AID will be processed by uracil DNA glycosylase (UNG) 
creating abasic sites leading to DNA double strand breaks as essential intermediates in 
CSR [61]. These DNA double strand breaks in two different switch (S) regions are joined 
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while leaving the intervening DNA segment as a circle (Figure 1.8). This exchanges the 
µ constant region of the immature immunoglobulin genes with one of the downstream 
constant segments (eg.γ) switching from IgM to a different isotype such as IgG. 
AID has also been implicated in DNA demethylation in the context of early 
embryogenesis in mammals [62-64] and it will be the main focus of this thesis work. The 
basis for this observation is in part on the reported ability of AID to deaminate 5-methyl 
cytosine (5mC) to thymine [54]. The proposed molecular processes of AID-dependent 
5mC deamination followed by DNA demethylation and the underlying principles of the 
research tools used to examine the 5mC deamination by AID will be discussed below. 
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1.3 Cytosine methylation as an epigenetic mark 
The tagging of cytosines with a methyl group in DNA (Figure 1.9) is a pivotal 
epigenetic mark in vertebrates. This provides an additional layer of information for 
growth and development which is not encoded in the primary sequence of DNA. The 
regulation of cytosine methylation in DNA has become an area of great interest in a 
number of fields including cell reprogramming [65] and differentiation [66], inhibition of 
retroelements [67], genomic imprinting [68] and X-chromosome inactivation [69]. As 
DNA methylation is required for normal development [70-71], aberrant methylation leads 
to several  human diseases including cancer [72]. 
 
 
Figure 1.9 DNA cytosine methylation. DNA methyltransferase (DNMT) catalyses the 
transfer of a methyl group (CH3) from S-adenosylmethionine to the 5
th carbon of cytosine 
in DNA. 
 
The methylation of DNA occurs predominantly in a CpG dinucleotide sequence 
context allowing symmetrical modification to facilitate inheritance through cell divisions. 
About 70-80% of cytosines in CpG sites are methylated on both strands in mammalian 
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somatic cells [68]. A genomic region of about 1 Kb that has a high G-C content (>55%), 
and also is rich in CpG dinucleotides but usually hypomethylated (lower level of 
methylation) is termed a “CpG island” [73]. Methylation of CpG islands in the promoters 
of genes results in gene silencing [68] whereas methylation of CpG islands within gene 
bodies regulate alternative promoter usage [74]. Furthermore, cytosine methylation in 
non CpG contexts (also known as CpH = CpA, CpC or CpT) has been found in human 
embryonic stem cells (ES) [75] and in adult mouse brain [76]. 
1.3.1 Methylation sites are hot spots for mutations 
Over 30 years ago 5mC was recognized as a hot spot for spontaneous C to T 
mutation at methylated cytosines in E.coli [77]. Since then several studies supported this 
finding both in E.coli and in humans. The E.coli K-12 genome codes for a single cytosine 
methyltransferase called Dcm [78] that methylates the second C in the sequence context 
CCWGG where W is A or T [79]. In addition to Dcm sites in lacI gene of E.coli, cI gene of 
phage λ [80] and gene for kanamycin resistance, kan [81] also contains mutational hot 
spots. Another important feature is that only some of the 5mCs are mutational hot spots 
in a given genomic region having multiple 5mCs. This observation was first made in the 
lacI gene of E.coli [77] and later in the human p53 mutation spectrum where only a 
fraction of methylated CpG sites were known hotspots [4]. Formation of a cruciform or 
other types of local secondary structures may determine the length of the time that the 
5mC is in unpaired state  determining the “temperature” of the hot spot [82]. The special 
proline codon of the kanamycin resistance genetic assay used in this study is located on 
a mutational hot spot [83]. 
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1.3.2. The intermediate of the 5mC to T mutation  
The two possible intermediates in the conversion of 5mC●G base pair into T:A  
are 5mC●A or T●G mismatches (Figure 1.10). The former mispair could be a result of 
misincorporation of an adenine during replication. However, there is no support for DNA 
polymerase copying a cytosine incorrectly when it is methylated [84]. Instead, hydrolytic 
deamination has been shown to convert 5mC into T [85-86] and therefore, the likely 
intermediate during the conversion of 5mC●G into T:A is T●G. There were a number of 
other hypotheses in the field to explain the origin of 5mC to T mutation through T●G 
mismatch [87-88] but their validity has been disputed. 
 
G
5mC
A
T
G
T
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5mC
 
Figure 1.10 The intermediate of 5mC●G to T:A mutation.  
 
1.3.3 Why 5mC to T mutation frequency is higher compared to C to T ? 
Comparison of mutational consequences of 5mC to T deamination with C to U 
deamination provides the evidence for underlying mechanisms. There are at least two 
reasons for higher mutation frequency of 5mC to T compared to C to U to T mutation 
(Figure 1.11). First, the deamination rate of 5mC is four fold higher compared to cytosine 
deamination [85]. A biological reason for this effect is that cells contain multiple efficient 
pathways to repair U●G mispairs compared to T●G mismatches [89]. The ubiquitous 
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enzyme Uracil-DNA glycosylase (UDG) is very efficient in removing uracils compared to 
VSP reapir of E.coli [90] or TDG/MBD4 of mammals [91] that have evolved to remove T 
from a T●G mismatch. 
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Figure 1.11 Comparison of C to T (A) versus 5mC to T (B) mutations and their     
repair mechanisms. BER: Base Excision Repair. 
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1.3.4. Mutational hot spots in human genes 
Analysis of DNA sequence changes in human genetic diseases revealed a high 
proportion of mutations at CpG sites [92]. This involves a number of human genetic 
diseases such as β-thalassmia, hypercholesterolemia, hemophilia and human cancer 
[93-95]. The enumeration of sequence changes in these genes revealed the mutation 
frequency at CpG sites was 15 fold higher compared to random chance [93]. In the case 
of human genetic diseases, it is hard to determine whether the mutations occurred 
“spontaneously” or due to external agents. However, the following examples provide 
evidence to support that at least the majority of the mutations arose spontaneously at 
CpG sites. When lacI and lacZ genes were inserted in mice, there were hot spots at 
CpG sequences for unselected C to T mutations [96-97]. Similar results were observed 
when lacI gene was inserted in rats [98].   
The study of p53 mutational spectra led to the understanding of this process in 
more details. Inactivation mutations in the p53 tumor suppressor gene are the single 
most common genetic event in human cancers that affects a specific gene. Most of the 
mutations lie on the gene segment of p53 gene that codes for the DNA binding region 
[99]. All CpG sequences analyzed in the p53 were completely methylated in all human 
tissue samples tested [4] and methylated CpGs contained more than one third of all 
cancer mutations. Five out of six p53 mutational hot spots (codons 175, 245, 248, 273 
and 282) had methylated CpG sites. Transition mutations at CpG sites of p53 were 
abundant in colorectal and brain cancers (www.p53.iarc.fr/index.html). 
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1.3.5 DNA methylation and DNMTs 
The enzymes that carry out DNA methylation, DNA methytransferases (DNMTs), are 
well conserved in mammals and plants [100]. There are two categories of DNMTs : de 
novo and maintenance methylatransferases [101]. The initial pattern of methylation is 
established by the two de novo methytransferses DNMT3A and DNMT3B (Figure 1.12) 
during early embryogenesis in mammals [71]. This established methylation pattern is 
faithfully maintained by the maintenance methyltransferase, DNMT1 during multiple cell 
divisions (Figure 1.12). DNMT1 prefers to act on hemi-methylated DNA and this helps 
the enzyme to carry out its function during DNA replication [102]. DNMT3B and DNMT1 
deficient mice are embryonic lethal [70-71] and DNMT3A null mice die around four 
weeks of age [71] confirming the requirement of these enzymes during development. 
1.3.6 DNA demethylation 
Studies done during the last decade have revealed that DNA methylation is a 
dynamic process in which the removal of the methyl group or DNA demethylation also 
takes place [103]. The DNA demethylation can occur via two processes called active or 
passive demethylation (Figure 1.12). Passive DNA demethylation occurs if the access of 
DNMT1 is blocked during successive DNA replication. This process is relatively well 
understood and accepted. In contrast, active DNA demethylation is a poorly understood 
enzymatic process that removes methyl groups [103].  DNA demethylation occurs both 
genome-wide during early embryogenesis [104] and gene-specifically when somatic 
cells responding to signals such as in activated T- lymphocytes [105].  
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Figure 1.12 DNA methylation profile during the early embryogenesis. The de novo 
methyltransferases, DNMT3A and DNMT3B establish the initial methylation patterns. 
These methylation marks are maintained by the maintenance methyltransferase DNMT1 
during replication after each cell division. However, if the DNMT1 is excluded or 
inhibited, the methyl groups will be diluted away after each successive replication cycle 
leading to passive demthylation. In contrast, active demethylation takes place through an 
enzymatic process replacing the 5mC with a C. Adapted from a figure in reference [106]. 
 
 
 
27 
  
Genome-wide DNA demethylation occurs in mammalian development at two distinct 
stages (Figure 1.13). First, when primordial germ cells (PGC) have reached the 
embryonic gonads (in mouse embryonic day E10.5 to E13.5) and second, in the early 
embryo beginning in the zygote immediately after fertilization until the morula stage [107-
108]. What is striking here is that the paternal genome of the pronuclear zygote 
undergoes replication independent, genome-wide DNA demethylation during the first few 
hours after fertilization [104, 109].  Although plants carry out 5mC demethylation with the 
help of glycosylases such as Demeter and Demeter-like glycosylases, no mammalian 
counterparts of this class of enzymes have been found to date [63, 110]. 
 
Figure 1.13 The two major phases of genome-wide DNA demethylation in mammals. 
The solid arrows in the inner circle represent the time in which AID is expressed during 
embryogenesis. Adapted from a figure in reference [111].   
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1.3.7. AID dependent DNA demethylation 
 DNA deaminases and the Base Excision repair (BER) pathway have recently been 
proposed in DNA demethylation along with other proposed mechanisms (Figure 1.14) 
[112].  
 
Figure 1.14 Proposed mechanisms for active DNA demethylation. In plants, there is direct 
evidence for the removal of 5mC using 5mC-specific glycosylases like DME/ROS1 family 
of enzymes. In contrast, in mammals no efficient 5mC removal has been detected. Instead 
there are a number of proposed mechanisms with some experimental evidence. One 
model is based on DNA deamination followed by BER and the candidate deaminases are 
AID and APOBEC1. According to the model, the resulting thymine after 5mC deamination 
is removed by T●G mismatch specific glycosylases like MBD4 or TDG. Another recently 
proposed mechanism is based on the oxidation of 5mC by the TET (Ten Eleven 
Translocation) family of proteins followed by repair. A modified  figure from reference 
[113]. 
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Morgan et al first reported in 2004 that AID is expressed in primordial germ cells 
(PGC) and in early embryos at a time when demethylation occurs [54] (Figure 1.13). This 
suggestion received strong support from three recent publications. In Zebra-fish embryos, 
up regulation of AID correlates with DNA demethylation and coexpression of the 
glycosylase MBD4 through transfection results in DNA demethylation at specific 
embryonic stages [64].  Popp et al used bisulfate/NextGen sequencing technology to show 
that in AID 
-/- mice, PGCs have  significantly higher methylation at many genomic loci than 
those from AID+/+ mice [63]. Using a system based on mouse-human cell fusions 
(heterokaryons), Bhutani et al showed that reprogramming of human cells to induced 
pluripotency required expression of AID [62]. Consequently, these studies strongly 
implicate a role for AID in DNA demethylation in early embryogenesis and PGCs.  
However, none of the papers clarify the mechanism by which AID promotes DNA 
demethylation. Conclusive evidence from both genetics and biochemistry are lacking to 
support the above role of AID. Genetically, AID knockout mice are viable and not sterile. 
Similarly, APOBEC1 knockout mice develop to adulthood and are fertile [114-115]. 
Biochemically, the activity of AID on 5mC is controversial (see below). As DNA 
methylation occurs symmetrically in the genomic DNA, deamination of both strands should 
give rise to T●G/G●T double mispairs. Since there is no evidence that either MBD4 or 
TDG act on a double mismatch, the proposed model (Figure 1.14) coupling AID 
/APOBEC1 with MBD4/TDG is questionable. Moreover, the repair of a double mismatch 
would lead to a DNA double strand break due to the activity of AP endonuclease that 
comes to process the two opposing abasic sites (Figure 1.14). There are several problems 
with this mechanism. First, if this mechanism were active, early zygotes would be under a 
great deal of stress repairing thousands of DNA demethylation-induced double strand 
breaks. In addition, as AID acts on single stranded DNA, it is not clear how AID would be 
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targeted to deaminate genomic DNA even before the first round of replication in the zygote 
[54]. Finally, it is not clear that AID can act on 5mC. A previous report in 2003 showed that 
5mC is a poor substrate for AID [116] and subsequently concluded that methylation of 
cytosine “protects” the base from AID promoted deamination [117]. Supporting this line of 
evidence, two recent papers contained data that showed AID is inefficient in deaminating 
5mC both in vitro [118] and in vivo [119]. One of the reasons this question remains 
unresolved is due to the difficulty of purifying the protein to perform in vitro assays. 
Therefore, in this study, I reexamined the ability of AID to deaminate 5mC using a powerful 
E. coli based genetic assay. 
1.4  E.coli as a model organism to study cytosine and 5mC deamination 
Uracils that arise from cytosine deamination, if unrepaired, results in a genomic C to 
T mutation after two rounds of replication (Figure 1.11). Since the mutation rate of the 
single stranded DNA is 140 fold higher than double stranded DNA, E. coli based genetic 
assays can be developed where the DNA is exposed as a single strand. One such 
biological process is transcription and several studies have examined the effect of 
transcription on cytosine deamination in E.coli. [120-122].  
Once AID was discovered and sequence similarity was compared to known proteins 
of the APOBEC family, the conserved sequence between AID and APOBEC1 led 
Muramatu et al [123] to propose an RNA editing activity for AID. The first evidence for 
AID being a DNA deaminase came from the early studies carried out in E.coli [124] 
where the authors showed that AID is a mutator in E.coli due to C to T mutations. The 
subsequent E. coli based assays reproduced a number of biological characteristics of 
the human enzyme [15, 55, 125]. When C to U to T mutations by APOBEC proteins are 
studied in E.coli, the sensitivity of the assay can be amplified by using an ung- strain 
[89]. The gene ung codes for UDG which is very efficient in removing uracil and initiating 
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the repair of the base through base excision repair pathway [126]. Hence, when the 
strain is deficient for ung, the majority of the C to T mutations are fixed in the genome. 
The same ung- phenotype can be obtained by expressing the inhibitor of UDG, Uracil 
DNA glycosylase Inhibitor (UGI), extra-chromosomally [127]. 
Methylation of cytosines in DNA is found in all three kingdoms of life and E.coli 
(eubacteria) uses it to recognize self from non-self. However, the presence of 5mC in 
DNA comes with a price of frequent deamination to T [85]. To study the 5mC 
deamination, one can use the Dcm methylation encoded by the E.coli [78] that 
methylates the second C in CCWGG sequence.  To study the 5mC deamination in other 
sequence contexts, methyl transferases from other organisms (M.HpaII from 
Haemophilus parainfluenzae and M.MspI from Moraxella species etc.,) can also be 
expressed in E.coli. However, since E.coli does not tolerate methylation sites other than 
Dcm, the experiments have to be carried out in methylation restriction deficient strains 
with mcrA-, mrr - genotypes. Moreover, if the detection of 5mC to T mutations is the goal 
of the study, an E.coli strain has to be selected with ung+ to avoid the C to U to T 
mutations. Furthermore, when the Dcm methylation is studied, a vsr - strain is required to 
stop the repair of 5mC to T mutations at the CCWGG sites. 
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1.5 Scope and aims of the research projects 
My thesis project focused mainly on two areas of the APOBEC family of proteins.   
1. Reexamination of the ability of AID to deaminate 5-methyl cytosine 
AID has recently been implicated in DNA demethylation based on its proposed role 
in 5mC deamination in early embryogenesis (Figure 1.14). However, the ability of AID to 
deaminate 5mC efficiently remains controversial. The major difficulty is the lack of pure 
AID protein for biochemical experiments.  In this project, I adapted a powerful and rapid 
genetic system to test this proposed new role for AID. The ability of AID to deaminate 
5mC was tested in five different sequence contexts including CpG and WRC. Other 
APOBEC proteins were also incorporated into the study to test the ability to deaminate 
5mC. Based on the genetic data obtained, biochemical experiments were designed to 
complement this study. 
2. Domain swap to determine the DNA binding regions of A3G and AID 
 Although APOBECs are DNA binding proteins with specific substrate preferences, 
the sequence determinants of the enzymes (e.g. which amino acid residues produce 
WRC sequence specificity in AID and last C of CCC in A3G) were not known. In this 
project a series of biochemical studies were carried out to verify the putative DNA 
binding sites predicted in the recent NMR [42] and X-ray crystal structures [44] of the 
A3G carboxy terminal domain. In this study, hybrid proteins were made by swapping the 
putative DNA binding regions between the two proteins AID and A3G; next I determined 
whether or not the hybrid proteins change the substrate specificities. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 Bacterial strains 
 E.coli strain BH143 [Δ(mrr-hsdRMSmcrBC)mcrA ɸ80dlacZΔM15 ΔlacX74 deoR 
endA1 araD139 Δ(ara, leu)7697 galU galK rpsL nupG Δ (dcm-vsr)] was used to insert 
the kan alleles into the bacterial chromosome. The strain was tested to verify whether it 
is dcm– through restriction digestion of transformed plasmid DNA into the BH143 (Figure 
2.1).  
 
   
Figure 2.1 Verification of BH143 for the absence of Dcm methylation. The E.coli 
strain DH10B wild type for dcm+ has been used as a control. The same plasmid DNA 
extracted from DH10B cannot be cleaved with PspGI (lane 3) but is digested when 
isolated from BH143 (lane 6), confirms that the latter strain does not express Dcm. 
BstNI is an isoschizomer of PspGI but is not sensitive to Dcm methylation. Uncut 
plasmid DNA from DH10B (lane1), DNA from DH10B cut with BstNI (lane 2), uncut 
DNA from BH143 (lane 4) and DNA from BH143 cut with BstNI (lane 5). 
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The Red/ET recombination system from Gene Bridges (Heidelberg, Germany) 
was used to insert the different kan alleles into the genome of the BH143 through 
recombineering (Figure 2.2). 
 
 
Figure 2.2 Construction of E. coli strains. The kan alleles were introduced into the manX 
gene in the E. coli chromosome through homologous recombination.The recombinants 
were selected using bleomycin-resistance conferred by the ble+ gene. 
 
The kan alleles in the plasmids pUP31, pUP41 and pUP44 [128] were amplified 
using the 70 mer primer pairs (Recombinant Forward and Recombinant Reverse) Table 
2.1) each of which contained 50 nucleotides identical to the manX gene in the genome. 
The amplification products containing the bleomycin resistance gene in addition to the 
kan alleles (kan-ble cassette prepared in advance) were used to construct the 
recombinants. Briefly, the PCR product was DpnI digested and gel purified to remove 
the traces of circular parental plasmid DNA. Red/ET recombination proteins-expression 
plasmid pRedET was transformed into BH143 using the E.coli pulser. Temperature 
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sensitive transformants were obtained incubating at 30°C, they were grown till OD600 
~0.3 and induced with L-arabinose to a final concentration of 0.3%. The cells were 
incubated at 37°C for 1 hour to express the Red/ET recombination proteins. The cells 
were spun down and made electro-competent by washing the pellet twice with chilled 
ddH2O and redissolving in 20-30 µL of water. 1-2 µL (~500 ng) of kan-ble cassette was 
electroporated into the competent cells. The cells were incubated for 3 hours at 37°C 
and plated on zeocin (20 µg/mL) plates. The recombinants obtained on zeocin plates 
were confirmed by PCR amplification and DNA sequencing. The three new strains were 
named BH400 (from pUP31), BH300 (pUP41) and BH500 (pUP44).  BH214 is BH158 
containing DE3 prophage, which contains the T7 RNA polymerase gene under the 
control of the lac promoter and has been described before [55]. For protein expression, 
E.coli B strain BL21DE3 or BL21DE3 codon+RIL (Stratagene) were used. 
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Table 2.1 Oligonucleotides used in genetic constructions and assays 
Name of the 
primer 
Sequence 
Recombinant 
Forward  
5´- GTT GAT ACA TGG GGA GGC AGC CCG TTC AAT GCT GCC AGC 
CGC ATT GTC GTC TGG ATA ATG TTT TTT GCG CCG  
Recombinant        
Reverse  
5´- GCA TTG GAA TGT TAA CGC CTG CAA TGA CTT CAT AAT GCT    
CTT TGT CGG AAA ACG GGA AGA CAC ACT CAT G  
UGI-F  5´-CCC GAA TTC TAG GAG TAC GAT AAT GAC AAA TTT ATC TGA 
CA  
UGI-R  5´-GGG GAA TTC TTA TAA CAT TTT AAT TTT ATT TTC TCC ATT AC  
A3A-F     5´- GGG GAC AAG CTT ATG GAA GCC AGC CCA G  
A3A -R     5´ - GGG GGG AAT TCT CAG TTT CCC TGA TTC  
AID-E58A-F     5´-CGG CTG CCA CGT AGC GCT GCT CTT CCT C  
AID-E58A-R     5´- GAG GAA GAG CAG CGC TAC GTG GCA GCC G  
A3A-E72A-F     5´- GGC CGC CAT GCG GCC CTG CGC TTC TTG  
A3A-E72A-R     5´- CAA GAA GCG CAG GGC CGC ATG GCG GCC  
pET-A3A-F     5´- GGA GGA ATT CAT GGA AGC CAG CCC AG  
pET-A3A-R     5´- GGG AGA GGC TCG AGG TTT CCC TGA TTC TG  
Kan-bleo-F     5´ -CGA CAC CAC TAA AGG CGT GCT  
Kan-bleo-R     5´-TGG AGC CGC TTT TGG TGC T  
 
2.2 Plasmids 
The pMB1-based plasmids carrying genes for M.HpaII [pM.HpaII,[83]], Dcm 
[pDCM21,[129]], and M.MspI [pQ8,[130]] have been described before. The plasmid 
pDCM22 contains dcm+ and vsr+ genes and has been described [129]. Human AID, 
APOBEC3A (A3A), and APOBEC3G (A3G) genes were cloned into p15A-based plasmid 
pSU24 creating respectively pSUAID, pSUA3A and pSUA3G (Figure 2.3). The primers 
used for the cloning are listed in the table 2.1. The clone for A3A cDNA was kindly 
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provided by Reuban Harris (University of Minnesota) and A3G cDNA was obtained from 
ATCC (Manassas, VA).  The gene for UGI was amplified from a plasmid kindly provided 
by Umesh Varshney (Indian Institute of Science, Bangalore, India) and inserted at an 
EcoRI site in pSUAID to create pSUAID-UGI. Catalytic mutants of AID (AID-E58A) and 
APOBEC3A (A3A-E72A) as well as hybrid genes A3G-AIDR1, A3G-AIDR1R2, pSUA3G-
AIDR2  were constructed using a whole plasmid PCR mutagenesis strategy [[131], 
(Table 2.1)]. For the purification of APOBEC3G carboxy terminal domain (A3G-CTD) or 
the A3G-AID hybrids (Figure 2.4), the genes were cloned into pGEX-6P-2 vector with a 
GST tag. Both A3A and the catalytic mutant A3A-E72A were amplified (Table 2.1) and 
cloned into pET28a (+) as EcoRI-XhoI fragments for purification. The hybrid genes A3G-
AIDR2 and AID-A3A were synthesized by DNA 2.0 (Menlo Park, CA) and A3G-AIDR2 
was cloned into pGEX-6P-2 and AID-A3AR2 was cloned into pSU24. 
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Figure 2.3 Salient features of the plasmid maps. The promoter (arrow), inserted gene/s, 
(light), tags (black, if present), origin of replication (mid gray) and the antibiotic 
resistance (dark gray) have been shown from left to right respectively.  
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Figure 2.4 Schematic of hybrid proteins combining segements of AID (green), A3G-CTD 
(red), or A3A (violet).  The swapped regions are illustrated as boxes.  
 
2.3 Kanamycin-resistance Reversion Assay 
The reversion assay has been described previously [81, 83]. To quantify 5mC to 
T deaminations, AID, AID-E58A, AID-A3AR2, A3A, A3A-E72A or A3G and one of the 
MTase genes (M.HpaII , Dcm  or M.MspI) were co-expressed from compatible plasmids 
and kanamycin-resistant revertants (50 µg/mL, phenotype-KanR) were scored. The KanR 
revertant frequency is given by the following ratio (Number of KanR revertants/Total 
number of viable cells). Twelve independent cultures were grown per condition and the 
median value was calculated using Mann-Whitney test using the GraphPad Prism 5 
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software. When the data were analyzed to quantify C to U deaminations, either UGI 
gene was expressed from the same plasmid as AID or and ung strain was used as the 
host. To study repair of T●G mispairs by VSP repair, the plasmid pDCM21 or pDCM22 
was introduced in BH400 and the KanR revertant frequencies were determined.  
 
2.4 Amplification of the kan alleles and sequence analysis 
A single colony from the center of a kanamycin containing plate was selected 
based solely on the location and not on the size. The cells from 12 independent plates 
per condition were dispersed in 30 µL sterile water and 2 µL of this mixture was used to 
perform PCR. A part of the kan-ble cassette covering the targeted proline codon that 
reverts to leucine or serine was PCR amplified using the two primers kan-ble-F and kan-
ble-R (Table 2.1) and the products were purified using PCR purification kit (Epoch-Life 
Science). The purified PCR products were sequenced using kan-ble-F as the primer. 
The sequences of revertants were compared to the wild type sequences of pUP31, 
pUP41 and pUP44 plasmid sequences using MacVector software (MacVector, Inc., 
Cary, NC) and the mutations were identified.  
2.5 Uracil Quantification Assay  
The genomic DNA was extracted and used for uracil quantification as described 
before [142]. Briefly, BH500 was co-transformed with M.MspI and either pSUAID or 
pSUAID-Ugi. The transformants were grown following the same conditions used for the 
KanR reversion assay. Purified genomic DNA was incubated with methoxyamine (100 
mM) for 90 minutes at 37 °C to block the pre-existing abasic sites (Figure 2.5).The DNA 
was ethanol precipitated and treated simultaneously with E. coli UDG (1 unit/0.1 µg of 
DNA, New England Biolabs) and aldehyde-reactive probe (2 mM, Dojindo Laboratories) 
for another 90 minutes at 37 °C.  DNA was transferred onto a positively charged nylon 
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membrane (Immobilon-Millipore) and cross linked to the membrane using a UV 
stratalinker 1800 (Beckman). The membrane was pre-equilibrated in Starting Block 
blocking buffer (Fisher) for 30 minutes and incubated with 5X10-4 mg/mL of streptavidin-
cy5 (GE Healthcare). The membrane was washed, dried and scanned using a 
phosphorimager (Typhoon 9210). The results were analyzed with ImageQuant software. 
The standard was generated using a single uracil containing 75-mer duplex. 
 
 
Figure 2.5 Scheme of the uracil quantification assay. DNA is first treated with 
methoxyamine (Mx) to block the pre-existing abasic sites. Uracil in DNA is next removed 
with E.coli uracil DNA glycosylase (UDG) and the resulting abasic sites are labeled with 
aldehyde-reactive probe (ARP). The DNA is then transferred to a positively charged 
nylon membrane and incubated with cy5-streptavadin. The membrane is scanned on a 
phosphorimager and the cy5 fluorescence is determined. Adapted from a figure in 
reference [142].  
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2.6 Purification of A3A and its mutant  
Human A3A gene and the catalytic mutant A3A-E72A were cloned into the EcoRI 
/XhoI sites of the pET28a (+) vector to construct A3A-His tag fusion gene and 
transformed into BL21DE3. The cell culture was grown at 37 °C till it reaches mid log 
phase. The transcription of the gene was induced with IPTG to a final concentration of 
0.2 mM. The cells were grown for another 5 hours at 20 °C and harvested by 
centrifugation. The cell pellet was resuspended in 25 mL of 1X Tris buffer [20 mM Tris-
HCl (pH7.5), 50 mM NaCl)] along with half a tablet of complete EDTA-free protease 
inhibitor (Roche diagnostics, Indianapolis,IN) and lysozyme (5 µg/mL).The cells were 
broken using the French Pressure Cell Press (Thermo Spectronic) and the cell free 
lysate was cleared by centrifugation. The lysate was passed over a Ni-NTA column 
(Novagen, Madison) to bind the his-tagged proteins. The bound proteins were washed 
with ~ 5 column volumes each of Tris buffer (20 mM Tris-HCl, 50 mM NaCl) and tris 
buffer containing 5 mM, 10 mM and 40 mM imidazole (Sigma-Aldrich) respectively. 
Finally, the bound A3A (or A3A-E72A) protein was eluted with 250 mM imidazole. 
Proteins from different fractions were separated on a 12% SDS-polyacrylamide gel. The 
final eluent containing the protein of interest was dialyzed using a Slide-A-Lyzer dialysis 
cassette (Thermoscientific, Rockford, IL). Proteins were concentrated using Amicon 
Ultra Centrifugal devices (Milipore, Billerica,MA). The concentrated proteins were 
equilibrated in the storage buffer (20 mM Tris-Hcl, 50 mM NaCl, 1 mM EDTA, 1 mM 
DTT, 10% glycerol).  
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2.7 Biochemical assay for C and 5mC deamination 
Cytosine deamination by A3A was studied using the oligomer A3A-C (Table 2.2). 
Six picomoles of oligomer were incubated at 37 °C with ~ 140 ng of A3A enzyme in a 10 
µL volume in deamination reaction buffer [40 mM Tri-HCl (pH 7.5), 5 mM EDTA, 1 mM 
DTT, 40 mM NaCl]. For the time course studies, the reaction mixtures were prepared 
scaling up six times the amount of a typical reaction. At indicated time points, 10 µL 
aliquots were removed and the reaction was stopped by adding 1, 10-phenanthroline 
(Sigma-Aldrich) to 5 mM. Two units of E. coli UDG (New England Biolabs) were added 
to the reaction and incubation was continued at 37 °C for one hour.  The reactions were 
stopped by adding NaOH to 0.1 M and heating to 95 °C for 7 minutes. A 15% 
sequencing gel was run to separate the products and the gel was scanned using 
Typhoon 9210. ImageJ software was used to quantify the intensities of the substrates 
and the deaminated products. 
5mC deamination by A3A was studied using the A3A-5mC oligo (Table 2.2). Two 
picomoles of the 5mC oligo were incubated with 140 ng of purified A3A protein (or A3A-
E72A) at 37 °C for 1 hour in a 10 µL volume in the deamination reaction buffer. The 
complementary G-containing oligo was mixed at three fold molar excess to create a T●G 
mismatch. The mixture was heated to 95 °C for 5 min and cooled slowly to room 
temperature over a period of 1 hour and placed on ice for 5 minutes to promote duplex 
formation. The duplex was incubated with 1.5 units of thermo stable thymine DNA 
glycosylase (Trevigen) for 1 hour at 47 °C in the thermocycler and the deaminated 
products were processed and analyzed similar to C-deamination. 
 
 
 
44 
  
Table 2.2 DNA oligomers used for in vitro deamination assay.   
 
 
2.8 Purification of A3G-CTD and A3G-AID hybrids 
The plasmids containing hybrid proteins with the GST tag were introduced in the 
bacterial strain BL21 DE3. The transformants were grown at 37 °C till OD600 ~ 0.5 in the 
presence of the antibiotic carbenecillin (50 µg/mL). The transcription of the wild type 
A3G or hybrid genes was induced by adding IPTG to a final concentration of 200 µM. 
The cells were grown at 24°C for 4 more hours and harvested by centrifugation. The cell 
pellet was dissolved in 30 mL of 1X Tris buffer (150 mM NaCl and 20 mM Tris-HCl, pH 
7.5) containing one tablet of the EDTA free protease inhibitor cocktail (Roche Diagnostic, 
Indianapolis,IN) and lysozyme (1 µg/mL). The cells were sonicated and the suspension 
was cleared by centrifugation. The glutathione-sepharose beads were added to the 
cleared lysate and mixed on a rocker for 30 minutes at 4 °C. The lysate was added to 
the column for glutathione-sepharose beads to pack along with GST tagged proteins. 
The bound proteins were washed with ~20 column volumes of 1X Tris buffer. Next, the 
bound proteins were eluted with the reduced glutathione (Sigma-Aldrich: in 50 mM Tris-
HCl, pH7.5). Different fractions of the eluates were run on a 12% SDS-PAGE gel to 
Name Sequence 
A3A-U     5’ - ATT ATT ATT ATT ATU GAT TTA TTT ATT TAT TTA TTT ATT T -3’ (6-
FAM) 
A3A-C 5’ - ATT ATT ATT ATT ATC GAT TTA TTT ATT TAT TTA TTT ATT T -3’ (6-FAM) 
A3A-T 5’-  ATT ATT ATT ATT ATT GAT TTA TTT ATT TAT TTA TTT ATT T -3’ (6-FAM) 
A3A-5mC 5’- ATT ATT ATT ATT ATO GAT TTA TTT ATT TAT TTA TTT ATT T -3’ (6-FAM)     
O = 5mC 
A3A reverse 
complement 
    5’- AAA TAA ATA AAT AAA TAA ATA AAT CGA TAA TAA TAA TAA T-3´ 
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identify the fractions with the wild type or hybrid proteins. The fractions containing the 
proteins were pooled and dialyzed using slide-A-Lyzer dialysis cassettes 
(ThermoScientific, Rockford,IL).  The proteins were concentrated using Amicon Ultra 
centrifugal filter devices according to the manufacturer’s instructions (Milipore, Billerica, 
MA). These proteins were further purified using ion-exchange chromatography in a 
MonoQ column (GE Healthcare). The protein was eluted using 0-1 M gradient of NaCl 
and collected in 1 mL fractions. The appropriate fractions of the hybrid proteins 
according to the UV absorption profile were pooled, concentrated and equilibrated with 
the storage buffer (25 mM Tris-pH7.5, 1 mM EDTA, 1 mM DTT and 10% glycerol).   
 
2.9 In vitro deamination activity assay with A3G-CTD and its hybrids 
A 17-mer oligomer with overlapping WRC and CCC sequences (Table 2.3) was 
used as the substrate to study the sequence specificities of the A3G-AID hybrid proteins. 
One picomole of the oligomer was labeled at the 5´ end with P33 using T4-PNK (New 
England Biolabs). The radio-labeled substrate oligo was incubated with 2 µg of the 
protein at 37 °C in a 10 µL volume in the deamination reaction buffer (25 mM Tri-HCl, 
pH7.5, 50mM NaCL, 1mM DTT, 1mM EDTA). When the time course studies were 
carried out, the reaction mixtures were scaled up six fold. At various time points (0, 2, 8, 
20, 60 minutes) 10 µL aliquots were removed from the master tube and the reactions 
were stopped by adding 1, 10 - phenanthroline (Sigma-Aldrich) to 5 mM. One unit of E. 
coli UDG (New England Biolabs) was added to the reactions and the incubation was 
continued at 37 °C for 45 min. The reactions were terminated by addition of NaOH to 
0.1M followed by heating to 95 °C for 7 min. The products were separated by 20 % 
PAGE. The gel was scanned using the Typhoon 9210 scanner.  ImageJ software was 
used to quantify the intensities of the gel bands. 
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Table 2.3 DNA oligomers used for deamination Assay 
Name Sequence 
CCC-17 5´- ATTATTACCCATTTATT 
UCC-17 5´- ATTATTAUCCATTTATT 
CUC-17 5´- ATTATTACUCATTTATT 
CCU-17 5´- ATTATTACCUATTTATT 
WRC-17 5´- ATTATTATACATTTATT 
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CHAPTER 3 
RESULTS 
3.1 Reexamination of the ability of AID to deaminate 5-methyl cytosine 
3.1.1 Validation of the genetic system for 5mC to T deamination 
 Our lab has previously used two defective alleles of the kanamycin-resistance 
gene (kan) that can be methylated in E.coli by different methyl transferases (MTase) to 
quantify 5mC to thymine conversions due to hydrolytic deamination [83]. In this plasmid 
based system the kan- alleles revert to kan+ (phenotype-KanR) through 5mC to T 
deamination increasing the KanR frequency by at least 10 fold. I adapted and expanded 
this system to study 5mC to T conversions by the AID/APOBEC family of proteins[132]. 
This new genetic system should be a better tool to reexamine the proposed role of AID 
to deaminate 5mC (Figure 1.16) as the purification of the protein is very hard.   
 To reduce the number of plasmids maintained in the cells and to increase the 
sensitivity of the assay, I constructed three E. coli strains (BH300, BH400 and BH500) 
each with a different kan allele inserted into the manX gene of the E. coli chromosome 
(Material and Methods Figure 2.1). Three different MTase genes on plasmids were 
introduced into the three strains to create five different sequence contexts for cytosine 
methylation (Figure 3.1). The sequences included CpG as well as WRC context 
preferred by AID. In other three sequence contexts, the methylated cytosine was in CpH  
where H is any nucleotide other than guanine (i.e. CpA, CpC, or CpT). Before testing the 
potential of AID to deaminate 5mC, the genetic system was characterized using four 
different validating techniques [see below 3.1.1 (A) - 3.1.1(D)] [132].  
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Figure 3.1 Sequence contexts of 5-methylcytosines in kan alleles. Three different kan 
genes are present in E.coli strains BH300, BH400 and BH500. The gene for the 
methyltransferase M.HpaII, M.MspI or Dcm was introduced in these strains to methylate 
one of the cytosines in a proline codon (underlined in the figure) to obtain five possible 
combinations. The methylated C is indicated with “M” above and five bases unique to 
each sequence context are indicated by a bracket below the sequence. 5mC to T 
conversion changes the proline codon to either leucine or serine and changes the 
cellular phenotype from kanamycin sensitive (KanS) to kanamycin resistant (KanR) 
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3.1.1- (A) Methylation protection of genomic DNA against restriction 
enzymes  
First the genetic system was validated testing that the chromosomal DNA in 
these strains was appropriately methylated. The genomic DNA from cells expressing 
M.HaII, Dcm or M.MspI was digested with HpaII, EcoRII or MspI respectively and was 
found to be resistant to the endonucleases (Figure 3.2). This observation confirms that 
all three MTases are active in E.coli and express the protein in enough quantities to 
methylate the entire genome at the respective cognate sites of the MTases.  
 
 
 
 
 
 
 
 
 
 
 
 
 
          
Figure 3.2 Protection of genomic DNA against restriction enzymes by the MTases. 
Genomic DNA resolved on a 0.8% agarose gel. 
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3.1.1- (B) Effect of MTase on the KanR reversion frequency  
The spontaneous KanR revertant frequencies in the presence and absence of the 
methyl transferases were compared to characterize the genetic system. With the 
presence of MTase, KanR reversion frequency went up ~ 100 fold in each case (Figure 
3.3) and this result is consistent with previously reported values [81, 83]. There is a 
chemical as well as a biological reason for the observed greater increase in KanR 
reversion frequency due to the presence of the MTases. Unlike cytosine to uracil, 5mC 
to thymine deamination rate is 4 times higher [85]. E.coli does not possess DNA 
glycosylases like MBD4 or TDG that excise thymines from T●G mismatches. 
Consequently, this control experiment confirms that MTase methylates the specific 
proline codon in the kan allele (Figure 3.1) and reverts either to leucine or proline due to 
hydrolytic deamination. The T●G mismatch specific endonuclease, Vsr has been deleted 
from the strains used for this assay (see the genotype in material and methods).  
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Figure 3.3 Effects of MTases on Kanamycin reversion frequency.  The KanR frequency 
with or without the MTase is shown. The E.coli strain used (BH300, BH400 or BH500) 
and the respective methylated sequences are shown. The genes for MTases M.HpaII, 
M.MspI or Dcm were introduced in the cells to methylate the DNA. The letter “M” within 
the sequence represents 5-methylcytosine and the horizontal line within the data points 
is the mean value. 
 
3.1.1-(C) Sequencing of the KanR revertants 
To characterize the new genetic system 12 independent KanR revertants from all 
three MTases were sequenced and nearly all the KanR revertants had the methylated 
cytosine changed to Thymine (Table 3.1). This validates the genetic system for proper 
reversion of the 5mC at the special proline codon.  
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Table 3.1 Sequences of spontaneous revertants as a ratio to the number of revertants 
sequenced. M is 5-methyl cytosine. The proline codon in the kan alleles that changes to 
serine or leucine is underlined.  
 
3.1.1-(D) Very Short Patch repair 
All of the control experiments carried out to validate the new genetic system 
confirmed the reliability of KanR reversion frequency to be used as an accurate measure 
of 5mC to T mutations in the system. Finally, the very short patch (VSP) repair 
mechanism of E.coli was utilized to verify that a majority of the revertants originate 
through the conversion of 5mC:G pair to T●G mispair. This was done by introducing the 
gene vsr+ in the strain BH400 in addition to Dcm. Vsr is a T●G mismatch specific 
endonuclease that hydrolyzes the phosphodiester linkage immediately 5´ of the 
mispaired T (Figure 3.4) initiating VSP repair that replaces the T with a C [133].  
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Figure 3.4 Very Short Patch repair (VSP) pathway of E.coli. VSP replaces T●G 
mismatches created by the deamination of one of the 5mC in the Dcm sequence 
(CCWGG) context. The Vsr endonuclease hydrolyzes the phosphodiester linkage 
immediately upstream of the mispaired T and DNA polymerase I (Pol I) and DNA ligase 
complete the reaction. M is 5methylcytosine. 
When the dcm+ gene alone was introduced in BH400 strain, KanR reversion 
frequency increased ~ 55 fold compared to the vector control. When both the dcm+ and 
vsr+ genes were introduced, the reversion frequency declined to only about 4 fold over 
the control (Figure 3.5). This result confirms that the 5mC to T mutation arises due to the 
methylation followed by deamination at the second C of CCWGG context. Therefore, all 
the validating results together confirmed that the novel genetic system can be used to 
quantify 5mC to T deaminations. 
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Figure 3.5 KanR revertant frequency with or without VSP repair. The KanR frequencies in 
the presence of only MTase (Dcm) or both Dcm and Vsr in the strain BH400 (sequence 
context CCWGG) is compared to the vector control. The mean value is shown as a 
horizontal line within the data points.  
 
3.1.2 Human AID: an efficient cytosine deamianse not a 5mC deaminase 
 When the human AID gene was introduced into BH500 without methyl 
transferase (MTase), the reversion frequency was ~ 10-6 (Figure 3.6). As BH500 is 
proficient in repairing U●G mismatches (ung+), the bulk of the uracil generated by 
cytosine deamination can be removed from the genome. To quantify the full extent of 
cytosine deaminations due to AID, the UDG inhibitor UGI was co-expressed. Expression 
of both AID and UGI increased the KanR reversion frequency ~ 200 fold confirming 
efficient cytosine deamination by the AID (Figure 3.6) [132].  
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Figure 3.6 Cytosine to uracil deamination by AID. KanR revertant frequencies in      
                  the strain BH500 due to AID alone or AID and UGI is compared.  
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 In contrast, when M.MspI was introduced to methylate proline codon of the kan 
allele along with AID in BH500, only a modest increase in 5mC deamination was 
detected in the KanR assay. Here, the reversion frequency due to AID was only 1.9 fold 
higher compared to the vector and 1.5 fold to the catalytic mutant of AID (Figure 3.7). 
This confirms that although AID is an efficient cytosine deaminase, it is not a 5mC 
deaminase in the same assay [132]. 
  
Figure 3.7 5-methyl cytosine to T deamination by AID. KanR revertant frequencies in 
BH500 expressing AID, AID-E58A mutant or vector alone are shown. M.MspI is present 
in all three conditions but not shown for the clarity. The median value is shown as a 
horizontal line within the data points.  
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Similarly, AID was inefficient in deaminating 5mC in four other sequence contexts 
including CpG (Figures 3.8).  
 
Figure 3.8 KanR revertants due to AID promoted 5mC to T deamination. Respective 
methyl transrerases are present in all conditions but not shown for the clarity. Median 
values are shown by a horizontal line. 
I wanted to verify that in cells where AID deaminates 5mC poorly, it was still 
deaminating cytosine efficiently. This was achieved by quantifying the genomic uracil 
accumulated due to AID activity using a biochemical assay. The assay labels the 
locations of the uracil with a Cy5 tag and uses Cy5 fluorescence to quantify the uracil 
levels (see Material and Methods Section 2.5). According to the results AID increases 
the amount of uracil in DNA by 10 fold (Figure 3.9) due to cytosine deamination; 
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however, 5mC to T deamination by AID is less than 2 fold (Figure 3.7) in the same cells 
[132].  
(A) 
 
 
(B) 
 
 
 
 
 
 
Figure 3.9 Quantification of genomic uracils due to AID. (A). Uracil containing oligo 
standard. (B).The amount of genomic uracils created by AID alone or AID and UGI is 
shown. The error bars indicate the standard deviation.  
AI
D
AI
D+
UG
I
0
100
200
300
400
500
600
700
800
900
1000
U
ra
ci
ls
/ 
m
il
li
o
n
 b
p
 
59 
  
3.1.3 Efficient 5mC deamination by other APOBEC proteins 
 Since AID is not an efficient 5mC deaminase, next I tested the ability of other 
APOBECs on 5mC deamination. APOBEC3G (A3G) was tested first because it is well 
characterized and a very important enzyme in retroviral restriction. As expected full 
length A3G expressed in an ung- E.coli strain (BH214) was very efficient in deaminating 
cytosines in its preferred substrate context (a run of C’s) compared to AID (Figure 3.10). 
However, when A3G was tested for 5mC deamination in the same sequence context, no 
increase in KanR reversion was detected (Figure 3.11).  
 
 
Figure 3.10 Comparison of cytosine to uracil deamination by AID and A3G. KanR 
revertant frequencies in BH300 strain expressing AID, AID-E58A mutant or A3G are 
shown. The mean value is shown as a horizontal line within the data points. 
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Figure 3.11 Comparison of 5mC to T deamination by AID and A3G. KanR revertant 
frequencies in BH300 strain with vector alone, AID or A3G with M.HpaII are shown. The 
median is shown as a horizontal line within the data points.  
 
Next, two APOBEC proteins (APOBE3A and APOBEC3C) that are localized to 
the nucleus were tested. APOBEC3A is not only an efficient cytosine deaminase (Figure 
3.12) but it also deaminates 5mC very efficiently (Figure 3.13 and 3.14). In contrast A3C 
showed some toxicity in E.coli (Figure 3.13). The ability of A3A to deaminate 5mC 
efficiently is dependent on its catalytic activity because A3A-E72A catalytic mutant 
showed a back ground level of reversion frequency (Figure 3.15). I also sequenced the 
independent revertants obtained in experiments in which cells were expressing both 
MTase along with AID or A3A. According to the sequences of the revertants, an 
overwhelming majority of the mutations occurred at the methylated cytosines (Table 
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3.2). Taken together, these data confirm that AID is not an efficient 5mC deaminase 
whereas A3A deaminates 5mC very efficiently in the same genetic system [132]. 
 
Figure 3.12 Comparison of cytosine to uracil deamination by AID, A3A and A3C. KanR 
revertant frequencies in BH500 strain expressing AID, AID-E58A mutant, A3A or A3C 
are shown. The mean is shown as a horizontal line.  
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Figure 3.13 Comparison of 5-methyl cytosine to T deamination by AID, A3A and A3C. 
KanR revertant frequencies in BH500 strain expressing AID, AID-E58A mutant, A3A or 
A3C are shown. MTase is present in all the conditions but not shown for the clarity. The 
mean is shown as a horizontal line.  
 
Figure 3.14 5-methyl cytosine deamination by A3A. KanR revertant frequencies in 
BH500 strain with vector alone, AID and A3A. MTase is present in all the conditions but 
not shown for the clarity. Horizontal line within data points is the median. 
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Figure 3.15 5-methyl cytosine deamination by A3A depends on catalysis. KanR revertant 
frequencies in BH500 strain with vector alone, A3A and the catalytic mutant E72A of 
A3A. MTase is present in all the conditions but not shown for the clarity. Horizontal line 
within data points is the median. 
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Table 3.2 Sequences of the revertants with AID/APOBEC. M is 5-methyl cytosine. The 
proline codon in the kan alleles that changes to serine or leucine is underlined.  
E. coli 
Strain 
MTase    Enzyme 
expressed 
Sequence of 
kan allele 
Revertant 
Sequence 
(Revertants with M to T 
change) /  (Number of 
revertants sequenced) 
BH400 Dcm AID TACMAGG TACTAGG 10/12 
BH400 Dcm A3A TACMAGG TACTAGG 12/12 
BH500 M.MspI AID TAMCGG TATCGG 11/12 
BH500 M.HpaII A3A TACMGG TACTGG 12/12 
 
3.1.4 In vitro cytosine and 5-methyl cytosine deamination by A3A 
 To complement the genetic data of 5mC deamination by A3A, the activity of the 
A3A was characterized in vitro using purified protein. A3A was cloned into an expression 
vector with a C-terminal His tag and purified partially over a Ni-affinity column (Figure 
3.16). The purified A3A was active and was able to completely convert cytosine into 
uracil in a synthetic oligonucleotide (Figure 3.17). Based on the purity of the protein 
(Figure 3.16), approximately 2 picomoles of the enzyme has reacted with 6 picomoles of 
the oligo within an hour.  
The purified A3A also deaminated 5mC efficiently. When an oligomer with a 
single 5mC was treated with the enzyme and processed as shown in the schematic 
(Figure 3.18) A3A treatment converted ~ 78% into product while converting ~99 % C to 
U. As expected, the catalytic mutant A3A-E72A did not convert 5mC to T (Figure 3.18). 
When the time-course of deamination by A3A was studied, a significant conversion of 
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5mC was detected even at the earliest time points (Figures 3.19 and 3.20). Due to 
technical difficulties there was some set to set variation in the data (Figure 3.20). 
However, the in vitro assays clearly confirmed that 5mC deamination by A3A is 
comparable to cytosine deamination [132]. Hence, both genetic and biochemical data 
confirm that A3A is an efficient deaminase of both C and 5mC.  
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Figure 3.16 SDS-PAGE gel of partially purified protein (or the mutant) over a Ni-affinity 
column. Wild type A3A is in lane 2 whereas A3A-E72A mutant is in lane 3. The protein of 
the size of APOBEC3A (28KDa) is indicated by an arrow.  
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(A )                                
 
(B)
 
Figure 3.17 in vitro cytosine deamination by A3A. (A) Schematic of the major 
steps of the in vitro assay. Fluoresently labeled (6-FAM) single stranded DNA 
oligomer with a single cytosine was treated with purified A3A and UDG. At 
indicated time points, the reaction was stopped by adding 1, 10-phenanthroline. 
The DNA strand was cleaved and electrophorased on a 12% polyacrylamide gel. 
(B) The oligomer with a uracil helps as a control to compare the size of the 
deaminated and cleaved product. The time incubated the oligo with the protein is 
indicated in minutes.  
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(A )                                
 
(B) 
 
Figure 3.18 in vitro 5 methyl cytosine deamination by A3A. (A) Schematic of the 
major steps of the in vitro assay. Fluoresently labeled oligomer with a single 
cytosine or 5mC was treated with purified A3A or the E72A mutant. The 5mC 
containing oligo was hybridized to its complement creating a T-G mismatch, treated 
with TDG, strand was cleaved and electrophorased on a 12% polyacrylamide gel. 
(B) The oligomers with a uracil(U), cytosine(C) and thymine(T) serve as  controls to 
compare the size of the deaminated and cleaved product as well as the efficiency of 
C versus 5mC deamination by A3A. 
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(A) 
 
(B) 
 
Figure 3.19 Kinetics of cytosine and 5mC deamination by A3A. (A) Single stranded 
DNA oligomers with a single C or 5mC were treated with A3A and reactions were 
stopped at indicated time points. The complementary strand was hybridized to the 
oligo and UDG or TDGwas added to cleave the DNA strand. DNA duplexes 
containing U●G and T●G mismatches servers as controls for the efficiency of 
reactions with UDG and TDG respectively. (B) Quantification of data in part (A) 
above. The data have been normalized for UDG and TDG reaction efficiencies. The 
density of the signal at time zero has been substracted from all data points.   
 
 
 
C-deamination 
5mC-deamination 
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Figure 3.20 Kinetics of A3A on cytosine versus 5mC deamination. The reactions 
conditions are similar to that of Figure 3.19. 
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3.2. Domain swap to determine the DNA binding regions of A3G and AID 
In this study we created segment swaps between the putative DNA binding 
regions predicted in solution structures of A3G and the respective conserved regions of 
AID (Figure 1.6). Although other APOBEC proteins have been less well studied, the 
substrate specificities of different enzymes have been examined. The variety of target 
sequences implies that the APOBEC family of proteins has evolved to target cytosines in 
different sequence contexts. Therefore, these proteins may be pliable enough to swap 
the DNA binding regions between the two proteins. The sequence specificity 
determinants of the proteins were verified using AID-A3G hybrid proteins in both genetic 
and biochemical assays [45].  
I studied the biochemical properties of the hybrid proteins to complement the 
genetic data obtained by two other graduate students in the lab. A more soluble variant 
of A3G-CTD called A3G-CTD-2K3A [42] was used to study biochemistry. 
3.2.1 Experimental design 
A former graduate student Dr. Michael Carpenter created the hybrids between 
AID and A3G using a whole plasmid PCR mutagenesis strategy [45, 131]. The 
construction of hybrids between AID and A3G is shown in Figure 2.3.  Once the activity 
of the hybrid proteins was verified in E. coli, they were tested using genetic assays. Dr. 
Michael Carpenter carried out Lac+ papillation assay and another graduate student 
Erandi Rajagurubandara performed rifamicin resistance (RifR) forward mutation assay to 
determine the sequence specificities of the hybrid proteins [45]. The broad-spectrum RifR 
assay [134] is well suited to detect the sequence specificity of the hybrid proteins.  
Mutations that occur in the rpoB gene confer resistance to the antibiotic rifampicin by 
changing the β-subunit of RNA polymerase. Sequencing of a portion (called cluster 2) 
using only two primer pairs covers a majority of the mutations in the rpoB gene. 
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3.2.2. Properties of AID hybrids containing A3G DNA binding regions  
AID-A3GR1 (AID containing A3G R1 DNA binding region) did not show A3G like 
sequence preference. This shows that region 1 of A3G alone is not sufficient to confer 
the sequence selectivity of A3G into AID. However, AID-A3GR2 was significantly more 
like A3G than AID in its targeting the last C in a run of cytosines in DNA. Moreover, AID-
A3GR1R2 promoted even higher sequence preference at CCC.  Hence, when both R1 
and R2 of A3G are introduced into AID, they cooperate in the hybrid protein to act like 
A3G on DNA at CCC sequences. 
 
 3.2.3 Properties of A3G hybrids containing AID DNA binding regions 
The introduction of only R1 from AID into A3G (A3G-AIDR1) behaved similarly to 
wild type A3G and had a mutation spectrum similar to A3G. However, the mutation 
spectrum of both the A3G-AIDR2 (A3G containing AID R2 binding region) and A3G-
AIDR1R2 were considerably different than that of either A3G or AID.   
To understand this new behavior of A3G-AID hybrids and also to complement the 
genetic data with biochemical data, I carried out in vitro deamination assays with the 
purified A3G-AID hybrid proteins (Figure 3.21).  
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Figure 3.21 SDS-PAGE (left) and western blot (right) of the affinity purified hybrid 
proteins. The right size of the proteins is indicated with two lines in both protein gel and 
the western blot. A3G-2K3A* - purified protein from glutathione affinity column followed 
by ion-exchange column.   
 
3.2.4 Biochemical properties of A3G-AID hybrids 
The single stranded DNA substrate used in the assay contained overlapping 
WRC and CCC sites to detect the deamination at both sites [Figure 3.22 (A)].  When wild 
type A3G was reacted with the oligonucleotide, it readily converted only the third 
cytosine in CCC to uracil but did not convert the first or the second cytosine in detectable 
levels [Figure 3.22 (B) and (C)]. The kinetics results confirm that A3G preferentially 
deaminates the third C over the first C [Figure 3.22 (C)] [45]. 
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Figure 3.22 Sequence selectivity and kinetics of A3G in cytosine deamination. (A) 
Sequence of the oligonucleotide substrate. (B) Image of a gel scan showing the kinetics 
of cytosine deamination by A3G. The left most lane contains the products of the three 
oligos with uracils replacing one of the three CCC as the control.  The length of 
incubation time is indicated in mins for the remaining lanes. (C). The kinetics of cytosine 
deamination based on the gel scan in part B. 
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A3G-AIDR1, like wild type A3G, showed a similar preference for the third 
cytosine in CCC over the first C [Figure 3.23 (A)].  In contrast to A3G-AIDR1, A3G-
AIDR2 and A3G-AIDR1R2 showed drastic differences in substrate specificities [Figure 
3.23 (B) and (C)] [45]. Both the enzymes converted the C in WRC at significant levels.  
However, both these enzymes retained the ability to deaminate the last C in CCC and 
therefore had the A3G-like specificity. Taken together, these results show that 
substitution of the DNA binding regions R1 and/or R2 regions of A3G with the 
corresponding regions in AID did not result in a replacement of A3G sequence specificity 
towards AID. Instead, it resulted in a broadening or relaxation of sequence preference to 
include WRC in addition to CCC sequence [45]. 
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(A) 
 
(B) 
 
(C) 
 
Figure 3.23 Kinetics of cytosine deamination by A3G-AID hybrids. Quantification of products 
created by (A). A3G-AIDR1, (B). A3G-AIDR2 and (C).A3G-AIDR1R2 
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3.2.5 DNA binding domain of A3A confers AID the ability to deaminate 5mC 
Based on the findings of the DNA binding domain (DBD) swap results, I 
hypothesized that A3A may contain a DNA binding region that can accommodate 5mC 
in its principal DBD. If this is true, replacement of DBD of AID with that of A3A may allow 
AID to deaminate 5mC. To test this possibility the hybrid protein was constructed by 
replacing the corresponding regions as shown (Figure 3.24 and Figure 2.4 Material & 
Methods). The hybrid protein was tested for 5mC deamination using the genetic assay. 
The chimeric protein AID-A3AR2 enhanced the KanR revertant frequency by 
approximately an order of magnitude compared to the vector control (Figure 3.25).  This 
suggests that the putative DBD of A3A has a portable 5mC deaminating motif [132].  
 
 
Figure 3.24 Schematic to illustrate domain swap between AID and A3A. The sequence 
of the putative DNA binding domains (DBD) of AID and A3A are shown. The principal 
DNA binding domain of A3A was identified by aligning the sequence of the A3A gene 
with that of AID. AID-A3AR2 contains all the amino acids except its DBD which is 
replaced with eight amino acids DBD from A3A. The amino acid residue numbers are 
indicated.   
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Figure 3.25 Comparison of 5mC deamination by AID, A3A and AID-A3AR2. KanR 
revertant frequency due the different proteins in BH500 strain is shown. The median is 
shown with a horizontal line within the data points.  
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CHAPTER 4 
DISCUSSION 
4.1 Reexamination of the ability of AID to deaminate 5-methyl cytosine 
 In this study I found that AID is not an efficient 5-methyl cytosine deaminase, 
although several recent publications controversially proposed that AID acts on 5mC 
(Figures 3.7 and 3.8). Instead APOBEC3A (A3A) showed a very high 5mC deamination 
in the same assay (Figures 3.13, 3.14 and 3.15). The complementary studies confirmed 
that A3A is efficient in deaminating 5mC in vitro as well (Figures 3.18 and 3.19). It 
should be pointed out that there have been no reported enzymes from any organism that 
has been shown to deaminate 5mC efficiently before.  
However, both AID and A3G converted cytosines into uracils efficiently. This 
efficient cytosine deamination capability of AID (Figure 3.6) in the same assay in which 
5mC to T conversion is very low (Figure 3.7) argues that the poor 5mC deamination 
activity by AID was not due to low level expression of the protein or its instability in 
E.coli. The ability of AID to deaminate 5mC was tested in all the relevant sequence 
contexts including CpG where the majority of 5mCs are found in mammalian cells, CpH 
shown to be having 5mC during embryogenesis as well as WRC preferred by AID. In all 
the cases the increase in 5mC to T mutations is less than two fold compared to the 
vector and therefore these results are inconsistent with the largely qualitative studies of 
Mogan et al [54] and the models that are based on 5mC deamination as the initiating 
step of DNA demethylation [62-63].  
 It is possible to argue that AID is not an efficient 5mC deaminase because a key 
accessory factor or a protein modification is not present in E.coli. Although possible, it is 
unlikely for several reasons. First, a number of studies have shown that AID is an 
efficient cytosine deaminase in E.coli and the novel genetic system reproduces the same 
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observation. Second, the only post translational modification of human AID purified from 
insect cells is serine38 phosphorylation [135] which is thought to affect its substrate 
specificity [136]. Even the AID protein purified from insects is 10 fold less efficient on 
5mC compared to acting on cytosine [116-117]. Third, I have shown here that AID can 
be converted to a more active 5mC deaminase by replacing its DNA binding domain with 
the corresponding region from A3A (Figures 3.24 and 3.25). This implies that A3A is 
capable of accommodating 5mC in its active site whereas AID does not have that ability. 
In fact a previous attempt to dock 2´-deoxycytidylate into the active site of A3G in our 
laboratory (Figure 4.1) using Auto Dock Vina (http://autodock.scripps.edu/) found that 
tyrosine 315 is the responsible amino acid that blocks the methyl group in 
accommodating in the catalytic pocket (M. Carpenter and A.S. Bhagwat unpublished 
data). 
 
Figure 4.1 Modeling of 2´-deoxycytidylate with APOBEC3G-CTD (PDB : 3E1U)  
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 Once the docking project suggested that Y315 is the principal cause that blocks 
the incorporation of 5mC in A3G and by analogy in AID catalytic pocket, I carried out a 
rational mutagenesis study to substitute the Y315 of A3G with other amino acids. The 
primary goal was to introduce a less bulky group so that the new catalytic pocket will 
allow room for the methyl group of 5mC. First, Y315A mutant was constructed using a 
site directed mutagenesis and tested for 5mC deamination. This mutant was catalytically 
inactive on both 5mC and cytosine. As Y315A could be a drastic amino acid change, the 
other amino acid substitutes were constructed using the oligo 
5´ACAAACACGTGAGCCTGTGCATCAAGACTGCACGCATCNNNGATGATTCAAGGA
AGAGCTCAG as the top strand in which NNN will code for the other amino acids at 315 
position. The mutants with Y315 substituting other amino acids also showed a reduced 
activity on cytosine deamination as shown by Figure 4.2.  
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Figure 4.2 KanR revertant frequency of A3G-CTD and its Y315 substituent mutants. 
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Homology modeling of AID and other APOBECs suggest that this tyrosine is 
equally positioned in AID and A3G whereas it is further away in A3A [137]. Therefore, 
the conserved tyrosine in the catalytic pocket of AID and A3G may be the principal 
cause for the poor ability of these enzymes to deaminate 5mC. Conserved Y130 in A3A 
is farther away from the catalytic pocket whereas that of A3G (Y315 of A3G-CTD) 
located in the catalytic pocket (Figure 4.3).  
 
 
 
Figure 4.3 Distinct DNA binding regions in A3A and A3G-CTD. The catalytic site pocket 
is highlighted in yellow. The conserved tyrosines in A3A (Y130) and in A3G-CTD (Y315) 
are circled in red for clarity. Adapted from a figure in reference [133].   
 In the novel genetic assay the introduction of MTases alone increased the KanR 
reversion frequency about two orders of magnitude (Figure 3.3 results section). Although 
this observation gave evidence for proper methylation of the proline codon which is key 
to the KanR assay, I was concerned about this high level of background as any enzyme 
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that deaminates 5mC should show an increase surpassing the threshold level of KanR 
reversion frequency due to MTase alone. This was the reason to test two additional 
APOBEC3 proteins A3A and A3C (shown to be localized to the nucleus) in the genetic 
system. The expression of A3C was toxic to E.coli and did not give consistent results in 
the assay. However, A3A was very efficient in deaminating 5mC in all the sequence 
contexts examined and showed at least 15 fold increase compared to the vector. This 
observation clearly confirmed the potential of the genetic assay to go beyond the level of 
background reversion frequency in the presence of MTase alone.  
 I confirmed that A3A deaminates 5mC biochemically by purifying the protein 
partially from E.coli and testing it in vitro for C and 5mC deamination. A3A deaminated 
both C and 5mC with a slight preference for C over 5mC. It should be noted that the 
efficiency of the Thymine DNA glycosylase enzyme (TDG) reaction is low and varied 
from reaction to reaction. The optimum temperature for the thermophilic TDG enzyme is 
65 °C and as the DNA duplex is unstable at that temperature, 47 °C was used. 
Consequently, we are underestimating the amount of 5mC deamination by A3A in the 
first step of the reaction. Regardless, these biochemical data complemented the genetic 
data that A3A is an efficient deaminase of 5mC.  
The finding that A3A is an efficient 5mC deaminase does not necessarily mean 
that this protein plays a major role in DNA demethylation in early embryogenesis. 
Although A3A has been shown to localize to the nucleus [138] there are no reports on its 
expression in embryonic tissues. Therefore, the biological role of A3A may be to inhibit 
human viruses and retrotransposons [17, 26], and to restrict foreign DNA [29].  
 However, there is some evidence to support the activity of A3A on 5mC in 
genomic DNA [31]. In this study a majority of the CpG sites of c-myc and p53 show 
either C to T or G to A mutations.  As in mammals about 70-80% of cytosines in CpG 
sites are methylated on both strands in somatic cells [68], at least by inference this 
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should represent the activity of A3A in deaminating 5mC to T on CpG sites. However, 
more studies are required in a mammalian system to warrant its true biological function 
based on 5mC deamination.  
 I have shown here that the AID-A3AR2 hybrid protein has the potential to 
deaminate 5mC efficiently. As this hybrid protein is still more AID like (190/198 amino 
acids), it would be interesting to repeat the experiments that have been done to show 
that AID plays a role in DNA demethylation [54, 62-64] to check whether the hybrid 
protein is going to enhance the effects that the authors had observed in above 
experiments.  
 A number of biochemical arguments can be raised against the DNA 
demethylation initiated through 5mC deamination by AID, A3A or any other cytosine 
deaminases in early embryogenesis. First, cytosine is the preferred substrate over 5mC 
for all APOBEC deaminases known. Since, there is about 30 fold abundance of 
cytosines compared to 5mC in mammalian genome, it is hard to visualize how the 
APOBECs deaminate 5mCs without deaminating cytosines overwhelmingly. Second, all 
APOBECs are single stranded deaminases. Therefore, the paternal genome of the 
zygote should have a mechanism to present a greater portion of the genome as a single 
strand to these enzymes even before the first round of replication and there is no 
evidence that this occurs. Third, a replacement of all 5mCs in the genome with cytosines 
through base excision repair would require several million repair events per cell and 
which could lead to DNA double strand breaks at CpG sites. Moreover, as the 
mammalian base excision repair depends on polymerase β  with an error rate of 1in 104 
[139], this would lead to an unacceptably high mutational load.  
 In summary, the results of the first project of my thesis work clearly showed that 
AID is not an efficient 5mC deaminase in five different sequence contexts including 
WRC. This strongly argues against the feasibility of the recently postulated role of AID in 
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DNA demethylation. Instead A3A showed efficient 5mC deamination both in vivo and in 
vitro. Moreover, the potential of A3A to deaminate 5mC lies in a segment of the protein 
that can be switched to confer 5mC deamination activity upon AID.  
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4.2 Domain swap to determine the DNA binding regions of A3G and AID 
 The hybrid proteins were constructed by swapping the putative DNA binding 
domains of A3G and AID to determine their actual DNA binding regions. The results 
indicate that about 10-12 amino acid segment within A3G (region 2, Figure 1.6) is the 
principal DNA binding region. When this region was introduced into AID framework, the 
sequence specificity of the hybrid protein (AID-A3GR2) changed from AID (WRC) to 
A3G like (CCC). However, when the opposite of this swap (to introduce region2 of AID 
into A3G) was done, the new hybrid protein A3G-AIDR2 did not change sequence 
specificity entirely from A3G (CCC) to AID (WRC). Instead, A3G-AIDR2 started acting on 
different sequence specificities according to the genetic data. I studied this broadening 
or relaxation of the sequence specificity using biochemical assays. The in vitro data 
suggest that the hybrid protein still retains the ability to act on CCC sequence context 
(Figure 3.23). Furthermore, the hybrid protein has displayed an additional ability to act in 
WRC. Hence, unlike A3G, the DNA binding region of AID is not sufficient to switch the 
sequence specificity of A3G from CCC to WRC.   
The introduction of only DNA binding region 1 either from A3G to AID or from AID 
to A3G did not change the specificity of the hybrid proteins. Instead it enhanced the 
sequence specificity conferred by the region2. This observation by genetic data is 
compatible with biochemistry as shown in [Figure 3.23 (A)] where A3G-AIDR1 acted on 
third C in CCC in contrast to WRC. However, the hybrid protein having R1 (A3G-
AIDR1R2) in addition to R2 (A3G-AIDR2) deaminated WRC rapidly compared to R2 
alone [Figure 3.23 (A) and (B)]. Another noticeable fact is that the CCC to CCU 
deamination is faster compared to the WRC to WRU [Figure 3.23 (A) and (B)]. The 
eventual decline of the product corresponding to CCU is obvious by the fact that the 
oligo was labeled at the 5´ end and the WRC is closer to the 5´ end than CCC. As a 
result once the uracil in WRU is converted to a nick to resolve in the gel, the downstream 
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sequence is lost. The apparent targeting of the last C in CCC earlier than WRC is hard 
to explain. A number of studies have shown that full length A3G binds single stranded 
DNA and slides in both directions. According to those studies, the enzyme targets 5´ end 
more frequently [140-141] though the hybrid proteins in this work show an opposite 
sequence preference. This observation could be due to several reasons. Whereas other 
studies have used the full length A3G, this work is based only on the carboxy terminal 
domain of the protein. Moreover, this work used a variant (2K3A) of A3G-CTD and 2K3A 
can deviate from its original processivity. The DNA oligomer used in this assay had both 
WRC and CCC overlapping sequences and this also can be a possible reason.  
 In summary, the results of the second project found that DNA binding region2 of 
A3G was the principal sequence-specificity determinant of the protein. Region1 
enhances the sequence specificity determined by region2. Both regions 1 and 2 of AID 
were not sufficient to confer its sequence specificity upon A3G. Replacement of region 2 
of A3G with corresponding region from AID relaxes the specificity of A3G. 
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 The AID/APOBEC family of proteins in higher vertebrates converts cytosines in 
DNA or RNA into uracil. These proteins have essential roles in either innate immunity or 
adaptive immunity. Recently, AID has also been implicated in DNA demethylation in the 
context of early embryogenesis in mammals. This is partly based on the reported ability 
of AID to deaminate 5-methyl cytosine to thymine (5mC to T). I reexamined this 
proposed new role of AID (5mC deamination) with two members of the APOBEC family 
in a novel Escherichia coli based genetic system. My results confirmed that while all 
three enzymes are strong cytosine deaminases, only APOBEC3A (A3A) is an efficient 
deaminator of 5mC. The partially purified A3A converted 5mC to T in vitro as well.  This 
is the first report of efficient deamination of 5mC by any enzyme from any organism. 
Although AID did not deaminate 5mC efficiently, when the DNA binding region of AID 
was replaced with the corresponding segment from A3A, the resulting hybrid protein 
deaminated 5mC efficiently. Together these results suggest that human AID deaminates 
5mCs very weakly. Consequently, AID is unlikely to promote genome-wide DNA 
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demethylation unless its ability to deaminate 5mC is enhanced through covalent 
modifications or accessory factors.  
APOBECs are DNA or RNA binding proteins with substrate preferences. 
APOBEC3G targets the last cytosine (C) in a run of Cs (usually three Cs) whereas AID 
prefers to act on WRC (where W is A or T and R is purine) in DNA. Guided by the 
solution structures of the APOBEC3G carboxy terminal domain (A3G-CTD), two putative 
DNA binding regions (R1 and R2) were recognized in the A3G-CTD structure. These 
potential DNA binding regions of A3G-CTD were swapped with the corresponding 
regions in AID. The biochemistry of the hybrid proteins A3G-AIDR1 (A3G protein 
containing AID DNA binding region 1), A3G-AIDR2 and A3G-AIDR1R2 were studied 
using an in vitro deamination assay. The data revealed that regions 1 and 2 of AID are 
not sufficient to confer its sequence-specificity upon A3G. Instead, replacement of 
Region 2 of A3G with corresponding region from AID broadens the specificity of A3G to 
act on WRC in addition to CCC.  
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